Auris Medical to Report Second Half and Full Year 2020 Financial Results and Provide Business Update on Wednesday, March 31, 2021

Rhea-AI Summary

Auris Medical Holding Ltd. (NASDAQ: EARS) will provide a business update and report financial results for the second half and full year 2020 on March 31, 2021. Following the announcement, management will host a conference call at 8:00 am ET. The company is focused on therapeutics for unmet medical needs in neurotology and CNS disorders. Key developments include AM-125 for vertigo in Phase 2, AM-201 in post Phase 1b, and two Phase 3 programs: Sonsuvi® for acute inner ear hearing loss and Keyzilen® for tinnitus.

Hamilton, Bermuda, March 24, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it will provide a business update and report its financial results for the second half and full year 2020 on Wednesday, March 31, 2021. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time).

To participate in this conference call, dial +1-877-870-9135 (US, toll free) or +44-2071-928-338 (international), and enter passcode 5649276. A live webcast of the conference call can be accessed in the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.

About Auris Medical

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Investor contact: 

investors@aurismedical.com

FAQ

What date will Auris Medical report its financial results for 2020?

Auris Medical will report its financial results on March 31, 2021.

What time is the conference call for Auris Medical's business update?

The conference call is scheduled for 8:00 am Eastern Time.

Which products is Auris Medical currently developing?

Auris Medical is developing AM-125 for vertigo, AM-201, and has two Phase 3 programs: Sonsuvi® for hearing loss and Keyzilen® for tinnitus.

What is the stock symbol for Auris Medical?

The stock symbol for Auris Medical is EARS.